| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Buddlejasaponin IVb targets multiple pathways including nitric oxide (NO) production in macrophages, NF-κB signaling, and Nrf2 pathway activation. It inhibits NO production with an IC50 of 4.2 μM in LPS-stimulated RAW 264.7 macrophages. It also inhibits PEDV-activated NF-κB signaling and downregulates cytokine levels (IL-6, IL-8, IL-1β, TNF-α).
|
|---|---|
| ln Vitro |
Buddlejasaponin IVb inhibits NO production in LPS-stimulated RAW 264.7 macrophages with an IC50 of 4.2 μM, which is 2.48-fold more potent than songarosaponin D under identical conditions. It exhibits antiviral activity against PEDV with an IC50 of 6.943 μM, a CC50 of 84.56 μM, and a selectivity index >10 in Vero cells. At 200 μM, it shortens thrombin time (TT) by 20.6%, indicating hemostatic efficacy.
|
| ln Vivo |
Buddlejasaponin IVb has demonstrated hepatoprotective effects by protecting liver cells from oxidative injury. It induces apoptosis in cancer cells and exerts cytotoxic effects against various cancer cell lines. The compound's anti-inflammatory effects have been validated in DSS-colitis models through dual NF-κB/Nrf2 pathway engagement.
|
| Enzyme Assay |
For NO inhibition assays, RAW 264.7 macrophages are stimulated with LPS and treated with varying concentrations of Buddlejasaponin IVb. Nitrite accumulation in culture medium is measured using the Griess reagent. IC50 values are calculated from dose-response curves. For thrombin time assays, plasma is incubated with the compound and thrombin, and clotting time is measured.
|
| Cell Assay |
Cellular assays are performed using RAW 264.7 macrophages stimulated with LPS. Cells are treated with Buddlejasaponin IVb at various concentrations, and NO production is measured by Griess assay. Cytokine levels (IL-6, IL-8, IL-1β, TNF-α) are quantified by ELISA from cell culture supernatants. NF-κB activation is assessed by Western blot or reporter gene assays.
|
| Animal Protocol |
In animal models, Buddlejasaponin IVb is administered at appropriate doses to evaluate anti-inflammatory and hepatoprotective effects. For DSS-colitis models, the compound is given orally or intraperitoneally, and disease activity index, colon length, and histological scores are assessed. For cancer studies, xenograft models are used to evaluate antitumor efficacy.
|
| ADME/Pharmacokinetics |
As a triterpene saponin with a molecular weight of 943.1 g/mol, Buddlejasaponin IVb has high polarity and poor oral bioavailability typical of saponins. It is likely metabolized by gut microbiota and undergoes enterohepatic circulation. Systemic exposure is limited, and tissue distribution may be affected by its large molecular size and glycosylation.
|
| Toxicity/Toxicokinetics |
Buddlejasaponin IVb has demonstrated a favorable safety profile in vitro with a CC50 of 84.56 μM in Vero cells, indicating a selectivity index >10 versus its antiviral IC50. In animal studies, the compound is well-tolerated at effective doses.
|
| References | |
| Additional Infomation |
According to reports, plants in the genus Stellaria contain Buddleja saponin Ivb, and relevant data are available for reference.
Buddlejasaponin IVb is a triterpene saponin with validated pharmacological benchmarks: NO inhibition IC50 = 4.2 μM in LPS-stimulated macrophages. It exhibits anti-inflammatory, antioxidant, anticancer, hepatoprotective, and hemostatic activities. It inhibits PEDV-activated NF-κB signaling and downregulates pro-inflammatory cytokines. |
| Molecular Formula |
C48H78O18
|
|---|---|
| Molecular Weight |
943.1221
|
| Exact Mass |
942.518
|
| CAS # |
152580-79-5
|
| PubChem CID |
91758420
|
| Appearance |
White to light brown solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1054.2±65.0 °C at 760 mmHg
|
| Flash Point |
591.3±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.634
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
66
|
| Complexity |
1810
|
| Defined Atom Stereocenter Count |
24
|
| SMILES |
O(C1([H])C([H])(C([H])(C([H])(C([H])(C([H])([H])[H])O1)O[H])OC1([H])C([H])(C([H])(C([H])(C([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])OC1([H])C([H])(C([H])(C([H])(C([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])C1([H])C([H])([H])C([H])([H])C2(C([H])([H])[H])C([H])(C([H])([H])C([H])([H])C3(C([H])([H])[H])C4(C([H])([H])[H])C([H])([H])C([H])(C5(C([H])([H])O[H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C5=C4C([H])=C([H])C32[H])O[H])C1(C([H])([H])[H])C([H])([H])O[H]
|
| InChi Key |
CXSXBHMYYCPTHP-QZXFRBLOSA-N
|
| InChi Code |
InChI=1S/C48H78O18/c1-22-31(54)38(65-40-36(59)34(57)32(55)25(18-49)62-40)39(66-41-37(60)35(58)33(56)26(19-50)63-41)42(61-22)64-30-11-12-44(4)27(45(30,5)20-51)10-13-46(6)28(44)9-8-23-24-16-43(2,3)14-15-48(24,21-52)29(53)17-47(23,46)7/h8-9,22,25-42,49-60H,10-21H2,1-7H3/t22-,25-,26-,27-,28-,29+,30+,31+,32-,33-,34+,35+,36-,37-,38+,39-,40+,41+,42+,44+,45+,46-,47-,48-/m1/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,4R,4aR,6aR,6bS,8S,8aS,14aR,14bS)-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,14a-dodecahydropicen-3-yl]oxy]-5-hydroxy-6-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~106.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0603 mL | 5.3016 mL | 10.6031 mL | |
| 5 mM | 0.2121 mL | 1.0603 mL | 2.1206 mL | |
| 10 mM | 0.1060 mL | 0.5302 mL | 1.0603 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
